Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
The historical rank and industry rank for CK Life Sciences International Holdings's Intrinsic Value: Projected FCF or its related term are showing as below:
CKLSF'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.76 Med: 1.42 Max: 1.93
Current: 1.39
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of CK Life Sciences International Holdings was 1.93. The lowest was 0.76. And the median was 1.42.
CKLSF's Price-to-Projected-FCF is ranked better than 70.38% of 260
companies
in the Biotechnology industry
Industry Median: 2.255
vs CKLSF: 1.39
CK Life Sciences International Holdings (OTCPK:CKLSF) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
CK Life Sciences International Holdings's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
0.0693
/
0.05861521325389
=
1.18
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings Intrinsic Value: Projected FCF Related Terms
CK Life Sciences International Holdings Intrinsic Value: Projected FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings Intrinsic Value: Projected FCF Chart
CK Life Sciences International Holdings Annual Data
CKLSF vs VRTX, REGN, RVMD: Intrinsic Value: Projected FCF Comparison
For the Biotechnology subindustry, CK Life Sciences International Holdings's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CK Life Sciences International Holdings Price-to-Projected-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CK Life Sciences International Holdings's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where CK Life Sciences International Holdings's Price-to-Projected-FCF falls into.
CK Life Sciences International Holdings Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $0.05 mean?
CK Life Sciences International Holdings (CKLSF) has a Intrinsic Value: Projected FCF of $0.05 as of Aug. 29, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on CK Life Sciences International Holdings and its competitors. According to the industry distribution chart, CK Life Sciences International Holdings ranks #77 out of 260 companies in the Biotechnology industry, placing it in the top 29.6%.
Is CK Life Sciences International Holdings' Intrinsic Value: Projected FCF too high?
CK Life Sciences International Holdings' current Intrinsic Value: Projected FCF is $0.05. The Biotechnology industry median Intrinsic Value: Projected FCF is 2.26. CK Life Sciences International Holdings' value of $0.05 is 97.8% below this industry median. Based on the distribution chart, CK Life Sciences International Holdings ranks #77 out of 260 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CK Life Sciences International Holdings has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CK Life Sciences International Holdings' Intrinsic Value: Projected FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CK Life Sciences International Holdings ranks #77 out of 260 companies for Intrinsic Value: Projected FCF. This puts CK Life Sciences International Holdings in the upper half of its industry. The industry median Intrinsic Value: Projected FCF is 2.26. CK Life Sciences International Holdings' value of $0.05 is 97.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Biotechnology company?
The median Intrinsic Value: Projected FCF among Biotechnology companies is 2.26, based on 260 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CK Life Sciences International Holdings's current Intrinsic Value: Projected FCF of $0.05 is 97.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on CK Life Sciences International Holdings and its competitors. For the Biotechnology industry, the median Intrinsic Value: Projected FCF is 2.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CK Life Sciences International Holdings's current Intrinsic Value: Projected FCF is $0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CK Life Sciences International Holdings stock overvalued right now?
Based on GuruFocus' analysis, CK Life Sciences International Holdings (CKLSF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.10, compared to a current price of $0.07 — trading 30.7% below its estimated fair value. The current Intrinsic Value: Projected FCF is $0.05 and 97.8% below the Biotechnology industry median of 2.26. CK Life Sciences International Holdings' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For CK Life Sciences International Holdings (CKLSF), the current Intrinsic Value: Projected FCF is $0.05 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CK Life Sciences International Holdings (CKLSF) Overvalued in 2026?
Based on GuruFocus' analysis, CK Life Sciences International Holdings stock appears to be undervalued.
The current stock price of $0.07 is trading 30.7% below its estimated GF Value™ of $0.10.
GuruFocus considers CK Life Sciences International Holdings to be Possible Value Trap.
Key valuation signals for CKLSF:
Intrinsic Value: Projected FCF: $0.05
GF Value™: $0.10 vs. price of $0.07 (30.7% below fair value)
Industry Position: 97.8% below the Biotechnology median (#77 of 260)
No single metric tells the full story. See the CKLSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.
34GF Score
Get the complete analysis for CKLSF
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CKLSF has been successfully added to your 
